AIRS vs LLY
AIRS: AirSculpt operates a proprietary, minimally invasive body contouring platform that removes fat and tightens skin through 31 treatment centers, competing with traditional liposuction and non-surgical fat reduction while benefiting from rising GLP-1 drug adoption. LLY: A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss franchises driving exceptional growth.
Side-by-side fundamentals
| Metric | AIRS | LLY | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $4.69 | $1,197.53 | |
| Market cap as of 2026-07-30 | $331M | $1.15T | |
| P/E as of 2026-07-30 | n/a | 45.62 | |
| PEG as of 2026-07-30 | n/a | 1.37 | |
| Net margin as of 2026-07-30 | -7.4% | +35.0% | LLY higher |
| Gross margin as of 2026-07-30 | +66.1% | +82.8% | LLY higher |
| Operating margin as of 2026-07-30 | -7.8% | +43.6% | LLY higher |
| ROE as of 2026-07-30 | -12.4% | +101.3% | LLY higher |
| ROA as of 2026-07-30 | -5.9% | +22.7% | LLY higher |
| Debt / equity as of 2026-07-30 | 0.45 | 1.39 | AIRS lower |
| Revenue growth (YoY) as of 2026-07-30 | -11.8% | +47.4% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | -3.5% | +31.7% | LLY higher |
| Dividend yield as of 2026-07-30 | n/a | +0.6% | |
| Dividend streak (yrs) SEC XBRL | 1 | 5 | LLY higher |
| Beta as of 2026-07-30 | 2.40 | 0.50 | |
| 1-year return as of 2026-07-27 close | -27.5% | +47.4% | LLY higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.